Tarsus Q3 sales rise 64% to $194.6 million; $668.3 million net loss on acquired R&D
Tarsus Pharmaceuticals reported third-quarter 2026 results in a press release furnished as Exhibit 99.1 to this 8-K. XDEMVY net product sales rose approximately 64% year over year to $194.6 million, but a $632.2 million acquired in-process R&D expense tied to the iRenix and Alkeus acquisitions pushed the net loss to $668.3 million, or $(14.40) per share, compared with $12.6 million, or $(0.30) per share, a year earlier.
Key points
- Third-quarter product sales, net were $194.6 million, compared with $118.7 million in the same period of 2025.
- Acquired IPR&D expense of $632.2 million included $551.2 million for Alkeus and $81.0 million for iRenix.
- Net loss was $668.3 million, or $(14.40) per share, versus $12.6 million, or $(0.30) per share, a year earlier.
- Cash, cash equivalents and marketable securities were $309.6 million as of September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.